Veeva Systems stock declines amid market caution
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Apr 07 2025
0mins
Source: Coinmarketcap
Veeva Systems (VEEV) closed at $172.52, down 1.21% from the previous day, underperforming the S&P 500's gain of 0.08%, indicating market caution regarding its future performance.
Despite analysts predicting an upcoming earnings report showing an EPS of $2.12, a 7.61% increase year-over-year, and revenue expected at $857.33 million, reflecting a 12.95% rise, the stock has dropped 10.7% over the past month, significantly worse than the Medical sector's decline of 6.98% and the S&P 500's 1.74% drop. This reflects relative weakness in the company's market position.
Analysts maintain an optimistic outlook on Veeva's profitability, currently rated #2 (Buy) by Zacks, despite the stock hitting a 52-week low.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy VEEV?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on VEEV
Wall Street analysts forecast VEEV stock price to rise
23 Analyst Rating
16 Buy
6 Hold
1 Sell
Moderate Buy
Current: 154.850
Low
222.00
Averages
317.10
High
380.00
Current: 154.850
Low
222.00
Averages
317.10
High
380.00
About VEEV
Veeva Systems Inc. is a provider of cloud solutions for the global life sciences industry. It offers span cloud software, data and business consulting and is designed to meet the needs of its customers and strategic business functions from research and development (R&D) through commercialization. Its product categories include Veeva Development Cloud, Veeva Quality Cloud, Veeva Commercial Cloud and Veeva Data Cloud. Veeva Development Cloud includes application suites for the clinical, regulatory, and safety functions of life sciences companies, all built on its Veeva Vault platform. Veeva Quality Cloud unifies applications, processes and partners across content management, training, quality management, assurance and control lab solutions on the Veeva Vault platform. Veeva Commercial Cloud is a product category comprised of software and analytics solutions. It owns Ostro, a brand engagement platform for life sciences that gives an artificial intelligence (AI)-driven chat experience.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Veeva and Adobe: Investment Opportunities in the AI Era
- Strong Financial Performance: Despite a declining stock price, Veeva Systems reported a 16% year-over-year revenue increase to $882.9 million in Q1 FY2027, with adjusted EPS at $2.24, reflecting robust demand and a solid customer base in the life sciences sector.
- Significant Market Opportunity: Veeva Systems has an addressable market exceeding $20 billion, while its trailing twelve-month revenue stands at only $3.3 billion, indicating substantial potential for future growth and expansion.
- AI Technology Integration: The launch of Veeva AI aims to automate and simplify numerous tasks within the life sciences industry, enhancing product competitiveness and customer satisfaction.
- Adobe's Growth Potential: Adobe's revenue increased by 13% year-over-year to $6.62 billion in Q2 FY2026, with adjusted EPS at $5.96, demonstrating its continued leadership in digital content creation, while the introduction of AI tools is significantly boosting its annual recurring revenue.
See More
Software Companies Embrace AI Opportunities
- Optimistic Industry Outlook: Nvidia CEO Jensen Huang stated at a tech trade show that AI will enhance software companies' products and services rather than replace them, providing a positive signal for the software sector and potentially prompting investors to revisit undervalued stocks.
- Veeva Systems Strong Growth: Veeva Systems reported a 16% year-over-year revenue increase in Q1 FY2027, reaching $882.9 million, with adjusted EPS at $2.24, highlighting strong market demand and customer loyalty in the life sciences sector.
- Adobe's Solid Financial Performance: Adobe's revenue grew 13% year-over-year in Q2 FY2026 to a record $6.62 billion, with adjusted EPS at $5.96, demonstrating the company's continued leadership in digital content creation despite market challenges.
- AI Tools Driving Innovation: Adobe's AI innovations have led to a threefold increase in annual recurring revenue to over $500 million, indicating the company's potential to leverage AI for enhancing products and services, further solidifying its competitive advantage.
See More
Software Companies Set to Benefit from AI Technology
- Optimistic Industry Outlook: Nvidia CEO Jensen Huang stated at a tech trade show that AI will enhance software companies' products and services rather than replace them, creating new investment opportunities for the software sector amid current market downturns.
- Veeva Systems Growth: In Q1 of fiscal year 2027, Veeva Systems reported a 16% year-over-year revenue increase to $882.9 million, with adjusted EPS at $2.24, reflecting strong performance and demand in the life sciences sector.
- Adobe's Financial Stability: Adobe's revenue in Q2 of fiscal year 2026 rose 13% year-over-year to a record $6.62 billion, with adjusted EPS at $5.96, indicating robust fundamentals despite leadership changes affecting its stock performance.
- Impact of AI Tools: Adobe's AI innovations have driven a threefold increase in annual recurring revenue to over $500 million, demonstrating that ongoing investments in AI will support long-term growth and enhance its competitive position in the market.
See More
Burry Increases Stakes in Adobe and Veeva Stocks
- Increased Adobe Holdings: Burry purchased Adobe shares at $199.59 each, despite a nearly 7% drop post-earnings report, indicating strong long-term profitability with a gross margin near an all-time high of 89.4%.
- Investment in Veeva: He bought Veeva stock at $159.05, which has declined nearly 30% year-to-date, yet its price-to-earnings and price-to-sales ratios are significantly below historical levels, suggesting market undervaluation amid strong adoption of its cloud software in the pharmaceutical sector.
- Market Sentiment Analysis: On Stocktwits, retail sentiment for Adobe remains ‘extremely bullish’, while Veeva is ‘bearish’, reflecting divergent investor expectations that could influence future market performance.
- Emergence of Value Stocks: Burry noted on his Substack that the market is witnessing a bifurcation between extreme value and extreme overvaluation, suggesting that some undervalued U.S. stocks may perform well during a market crash, highlighting a focus on value investing.
See More
UCB Partners with Veeva to Enhance Safety Management
- Unified Safety Management: UCB standardizes its global safety processes using Veeva Safety Suite, aiming to enhance operational efficiency and scalability, thereby accelerating case processing and optimizing regulatory submissions.
- Automation Drives Efficiency: By leveraging Veeva's automation tools, UCB promotes contactless case handling, ensuring higher transparency and coordination in safety data management, which enhances patient medication safety.
- Enhanced Data Analysis Capabilities: The introduction of Veeva Safety Workbench enables more efficient data analysis, supporting rapid and scalable report generation, further improving UCB's performance in global compliance.
- Strategic Partnership Outlook: UCB's strategic collaboration with Veeva not only simplifies pharmacovigilance activities but also drives advanced automation through standardized processes, ensuring that patients receive safe and effective medications.
See More
UCB Partners with Veeva to Enhance Safety Operations
- Global Safety Unification: UCB's collaboration with Veeva Safety Suite aims to enhance operational efficiency in global safety operations through a unified platform, thereby accelerating adverse event processing, improving regulatory compliance, and enhancing patient safety.
- Process Automation Optimization: UCB will leverage Veeva Safety's automation capabilities to streamline the reception, processing, and submission of adverse events, which is expected to significantly improve operational efficiency and reduce human errors, ensuring data accuracy and reliability.
- Enhanced Data Analysis Capability: With advanced data analytics from Veeva Safety Workbench, UCB can quickly generate scalable reports, further improving its ability to detect safety signals, thus enhancing the company's competitiveness in the drug safety sector.
- Strategic Partnership Outlook: The strategic partnership between UCB and Veeva not only aids in standardizing global pharmacovigilance but also drives innovation capabilities within the biopharmaceutical industry, ensuring the delivery of safe and effective medications to patients.
See More
Veeva and Adobe: Investment Opportunities in the AI Era
- Strong Financial Performance: Despite a declining stock price, Veeva Systems reported a 16% year-over-year revenue increase to $882.9 million in Q1 FY2027, with adjusted EPS at $2.24, reflecting robust demand and a solid customer base in the life sciences sector.
- Significant Market Opportunity: Veeva Systems has an addressable market exceeding $20 billion, while its trailing twelve-month revenue stands at only $3.3 billion, indicating substantial potential for future growth and expansion.
- AI Technology Integration: The launch of Veeva AI aims to automate and simplify numerous tasks within the life sciences industry, enhancing product competitiveness and customer satisfaction.
- Adobe's Growth Potential: Adobe's revenue increased by 13% year-over-year to $6.62 billion in Q2 FY2026, with adjusted EPS at $5.96, demonstrating its continued leadership in digital content creation, while the introduction of AI tools is significantly boosting its annual recurring revenue.
See More
Software Companies Embrace AI Opportunities
- Optimistic Industry Outlook: Nvidia CEO Jensen Huang stated at a tech trade show that AI will enhance software companies' products and services rather than replace them, providing a positive signal for the software sector and potentially prompting investors to revisit undervalued stocks.
- Veeva Systems Strong Growth: Veeva Systems reported a 16% year-over-year revenue increase in Q1 FY2027, reaching $882.9 million, with adjusted EPS at $2.24, highlighting strong market demand and customer loyalty in the life sciences sector.
- Adobe's Solid Financial Performance: Adobe's revenue grew 13% year-over-year in Q2 FY2026 to a record $6.62 billion, with adjusted EPS at $5.96, demonstrating the company's continued leadership in digital content creation despite market challenges.
- AI Tools Driving Innovation: Adobe's AI innovations have led to a threefold increase in annual recurring revenue to over $500 million, indicating the company's potential to leverage AI for enhancing products and services, further solidifying its competitive advantage.
See More
Software Companies Set to Benefit from AI Technology
- Optimistic Industry Outlook: Nvidia CEO Jensen Huang stated at a tech trade show that AI will enhance software companies' products and services rather than replace them, creating new investment opportunities for the software sector amid current market downturns.
- Veeva Systems Growth: In Q1 of fiscal year 2027, Veeva Systems reported a 16% year-over-year revenue increase to $882.9 million, with adjusted EPS at $2.24, reflecting strong performance and demand in the life sciences sector.
- Adobe's Financial Stability: Adobe's revenue in Q2 of fiscal year 2026 rose 13% year-over-year to a record $6.62 billion, with adjusted EPS at $5.96, indicating robust fundamentals despite leadership changes affecting its stock performance.
- Impact of AI Tools: Adobe's AI innovations have driven a threefold increase in annual recurring revenue to over $500 million, demonstrating that ongoing investments in AI will support long-term growth and enhance its competitive position in the market.
See More
Burry Increases Stakes in Adobe and Veeva Stocks
- Increased Adobe Holdings: Burry purchased Adobe shares at $199.59 each, despite a nearly 7% drop post-earnings report, indicating strong long-term profitability with a gross margin near an all-time high of 89.4%.
- Investment in Veeva: He bought Veeva stock at $159.05, which has declined nearly 30% year-to-date, yet its price-to-earnings and price-to-sales ratios are significantly below historical levels, suggesting market undervaluation amid strong adoption of its cloud software in the pharmaceutical sector.
- Market Sentiment Analysis: On Stocktwits, retail sentiment for Adobe remains ‘extremely bullish’, while Veeva is ‘bearish’, reflecting divergent investor expectations that could influence future market performance.
- Emergence of Value Stocks: Burry noted on his Substack that the market is witnessing a bifurcation between extreme value and extreme overvaluation, suggesting that some undervalued U.S. stocks may perform well during a market crash, highlighting a focus on value investing.
See More
UCB Partners with Veeva to Enhance Safety Management
- Unified Safety Management: UCB standardizes its global safety processes using Veeva Safety Suite, aiming to enhance operational efficiency and scalability, thereby accelerating case processing and optimizing regulatory submissions.
- Automation Drives Efficiency: By leveraging Veeva's automation tools, UCB promotes contactless case handling, ensuring higher transparency and coordination in safety data management, which enhances patient medication safety.
- Enhanced Data Analysis Capabilities: The introduction of Veeva Safety Workbench enables more efficient data analysis, supporting rapid and scalable report generation, further improving UCB's performance in global compliance.
- Strategic Partnership Outlook: UCB's strategic collaboration with Veeva not only simplifies pharmacovigilance activities but also drives advanced automation through standardized processes, ensuring that patients receive safe and effective medications.
See More
UCB Partners with Veeva to Enhance Safety Operations
- Global Safety Unification: UCB's collaboration with Veeva Safety Suite aims to enhance operational efficiency in global safety operations through a unified platform, thereby accelerating adverse event processing, improving regulatory compliance, and enhancing patient safety.
- Process Automation Optimization: UCB will leverage Veeva Safety's automation capabilities to streamline the reception, processing, and submission of adverse events, which is expected to significantly improve operational efficiency and reduce human errors, ensuring data accuracy and reliability.
- Enhanced Data Analysis Capability: With advanced data analytics from Veeva Safety Workbench, UCB can quickly generate scalable reports, further improving its ability to detect safety signals, thus enhancing the company's competitiveness in the drug safety sector.
- Strategic Partnership Outlook: The strategic partnership between UCB and Veeva not only aids in standardizing global pharmacovigilance but also drives innovation capabilities within the biopharmaceutical industry, ensuring the delivery of safe and effective medications to patients.
See More
